SEC Form 4 · accession 0001628656-15-000004
MYRIAD GENETICS INC · MYGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bernard Tobin
Officer — President Crescendo BioScience
Period of report
Jan 2, 2015
Accepted (ET)
Jan 6, 2015 · 2:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899923
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2015 | A | 12,000 | $0.00 | A | 12,000 | D | |
| Common Stock | Jan 2, 2015 | A | 28,000 | $0.00 | A | 40,000 | D | |
| Common Stock | Jan 2, 2015 | F | 4,720 | $34.61 | D | 35,280 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Restricted stock units granted and immediately vested upon employment.
- F2Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% per year over a four-year period on each anniversary of the date of grant.